EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 23 / No 11 (Novembre 2007) Med Sci (Paris), 23 11 (2007) 957-960 References
Free Access
Issue
Med Sci (Paris)
Volume 23, Number 11, Novembre 2007
Page(s) 957 - 960
Section M/S revues
DOI https://doi.org/10.1051/medsci/20072311957
Published online 15 November 2007
  1. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282 : 1264–9 [Google Scholar]
  2. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28 : 137–52. [Google Scholar]
  3. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338 : 1128–37. [Google Scholar]
  4. Bérard A, Oraichi D. Development of a surveillance and signal detection system to monitor medication exposure during pregnancy and lactation. Pharmacoepidemiol Drug Saf 2004; 13 : S1-334 (253). [Google Scholar]
  5. US Department of Health and Human Services. Mental health : a report of the surgeon general. Executive summary of 1999. http://www.surgeongeneral.gov/library/mentalhealth/pdfs/c4.pdf. [Google Scholar]
  6. International Clearinghouse for Birth Defects Monitoring Systems, Annual report Rome : ICBDMS, 2003. [Google Scholar]
  7. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy : fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26 : 44–8. [Google Scholar]
  8. Ramos E, Oraichi D, Rey E, et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. Br J Obstet Gynecol 2007; 114 : 1055–64. [Google Scholar]
  9. Health Canada. Health Canada endorsed important safety information on Paxil (paroxetine), 2005. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2005/paxil_3_hpc-cps_f.html [Google Scholar]
  10. US Food and Drug Administration. FDA Public Health Advisory Paroxetine of 2005. http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm [Google Scholar]
  11. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354 : 579–87. [Google Scholar]
  12. Bérard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants : the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80 : 18–27. [Google Scholar]
  13. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63 : 898–906. [Google Scholar]
  14. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295 : 499–507. [Google Scholar]
  15. Lou HC, Hansen D, Nordentoft M, et al. Prenatal stressors of human life affect fetal brain development. Dev Med Child Neurol 1994; 36 : 826–32. [Google Scholar]
  16. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995; 17 : 165–71. [Google Scholar]
  17. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995; 15 : 778–80. [Google Scholar]
  18. Buist A. Perinatal depression : assessment and management. Aust Fam Physician 2006; 35 : 670–3. [Google Scholar]
  19. Beck CT. The effects of postpartum depression on maternal-infant interaction : a meta-analysis. Nurs Res 1995; 44 : 298–304. [Google Scholar]
  20. Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43 : 225–37. [Google Scholar]
  21. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991; 148 : 1234–6. [Google Scholar]
  22. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995; 56 : 17–20. [Google Scholar]
  23. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153 : 1132–7. [Google Scholar]
  24. Baum AL, Misri S. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harv Rev Psychiatry 1996; 4 : 117–25. [Google Scholar]
  25. Ramos E, St-André M, Rey E, Bérard A. Risk of congenital malformations associated with duration of exposure to antidepressants during the gestational period. Br J Psychiatry 2007 (accepté pour publication). [Google Scholar]
  26. Blier P. Pregnancy, depression, antidepressants and breast-feeding. J Psychiatry Neurosci 2006; 31 : 226–8. [Google Scholar]
  27. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161 : 22–9. [Google Scholar]
  28. Rubinow DR. Antidepressant treatment during pregnancy : between Scylla and Charybdis. Am J Psychiatry 2006; 163 : 954–6. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.